Close Window


  1. Wujcik D. Infection. In: Groenwald SL, Goodman M, Frogge MH, Yarbro CH, eds. Cancer Symptom Management. Boston, Mass: Jones and Bartlett Publishers; 1986:289-304.


  2. The Merck Manual of Medical Information—Home Edition Online. Available at: http://www.merck.com/pubs/mmanual_home/sec15/166.htm. Accessed February 15, 2002.


  3. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med. 1991;325:164-170.


  4. Bertini M, Freilone R, Vitolo U, et al. P-VEBEC: a new 8-weekly schedule with or without rG-CSF for elderly patients with aggressive non-Hodgkin's lymphoma (NHL). Ann Oncol. 1994;5:895-900.


  5. de Graaf H, Willemse PHB, Bong SB, et al. Dose intensity of standard adjuvant CMF with granulocyte colony-stimulating factor for premenopausal patients with node-positive breast cancer. Oncol. 1996;53:289- 294.


  6. ADVANCE: Awareness of neutropenia in chemotherapy. 2001;1:3-4.7.


  7. Adams VR. Adverse events associated with chemotherapy for common cancers. Pharmacother. 2000;20(7 pt 2):96S-103S.


  8. Neulasta® (pegfilgrastim) [package insert]. Thousand Oaks, Calif: Amgen; 2002.


  9. Holmes FA, O'Shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle ver-sus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol. 2002;20:727-731.


  10. Green MD, Koelbl H, Baselga J, et al. A randomized, double-blind, phase 3 study evaluating fixed-dose, once-per-cycle pegylated filgrastim (SD/01) vs daily filgrastim to support chemotherapy for breast cancer. Proc Am Soc Clin Oncol. 2001;20:23a. Abstract 90.


  11. Gordon MS, Sosman JA. Clinical application of cytokines and biologic response modifiers. In: Hoffman R, Benz EJ, Shattil SJ, et al, eds. Hematology: Basic principles and practice. 3rd ed. New York, NY: Churchill Livingstone; 2000:939-977.


  12. Ozer H, Armitage JO, Bennett CL, et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practical guidelines. J Clin Oncol. 2000;18:3558-3585.


  13. Dixon DO, Neilan B, Jones SE, et al. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. J Clin Oncol. 1986;4:295-305.


  14. Kwak LW, Halpern J, Olshen RA, et al. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol. 1990;8:963-977.


  15. Epelbaum R, Haim N, Ben-Shahar M, et al. Dose-intensity analysis for CHOP chemotherapy in diffuse aggressive large cell lymphoma. Isr J Med Sci. 1998;24:535-538.


  16. Chemotherapy and you. A guide to self-help during cancer treatment. National Cancer Institute. NIH Publication No. 99-1136. 1999.


  17. American Cancer Society. Cancer Facts & Figures 2007. Available at: http://www.cancer.org/docroot/stt/stt_0.asp (Accessed July 17, 2007).


  18. American Cancer Society. Ovarian cancer has early symptoms. First national consensus on common warning signs. Available at: http://www.cancer.org/docroot/
    NWS/content/NWS_1_1x_Ovarian_Cancer_Symptoms
    _The_Silence_Is_Broken.asp (Accessed July 19, 2007).


  19. Pirl, WF. Evidence report on the occurrence, assessment, and treatment of depression in cancer patients. J Natl Cancer Inst Monogr. 2004; 2004(32):32-39.


  20. American Cancer Society. Cancer, Anxiety and Fear. Available at: http://www.cancer.org/docroot/MBC/content/
    MBC_4_1X_Cancer_Anxiety_and_Fear.asp?sitearea =MBC (Accessed August 7, 2007)